Immunogenicity and predicitve factors for biological therapy treatment in rehumatoid arthritis - focused on abatacept
Abstract
Biological therapy (bDMARD) changed the approach for treatment of rheumatoid arthritis, it provided new opportunities, where treatment with traditional disease modifying drugs (sDMARD) failed. Failure of bDMARD therapy is aserious problem.
It is believed that up to one third of patients with RA suffers from rapid loss of potency bDMARD. One possible explanation is the immunogenicity of the monoclonal antibody protein leading to the formation of antibodies (Anti-drug antibodies (ADA)).
Prediction of risk factors for failure bDMARD would allow not only the choice of treatment targeted to the individual patient, but also early detection efficiency losses bDMARD before developing a relapse of RA. Abatacept is fusion protein with the ability of blocking costimulatory CD28 and CD80 / 86, which is required for full activation of T lymphocytes, which is considered bDMARD second line failure previous therapy tumor necrosis factor a (TNFa). immunogenicity fak-torů to find non-responders to the bDMARD